Towards Healthcare
Oral Diabetes Medicine Market Trends and Companies

Oral Diabetes Medicine Market Fueled by Tech Advances

The emerging need for oral medicines is due to the progression of diabetes, inadequate lifestyle management, and declining insulin production. North America dominated the market in 2024, driven by the growing aging population, innovative drug treatments, and improved access and affordability.

Content

  • Last Updated: 28 October 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The oral diabetes medicine market is evolving fast, with predictions of robust growth and high revenue fueled by technological advancements and healthcare demand.

North America is currently leading the oral diabetes medicine market share by 35% due to favorable regulatory and policy changes, patient-centric care, competitive pricing, and generics.

The oral diabetes medicine market includes 5 segments, such as drug class mechanism of action, therapeutic use indication, formulation product format, distribution channel, and region.

Key trends include innovations in oral formulations like GLP-1 and SGLT2 classes, multi-targeted oral therapies, increased access to generic oral drugs, patient-centric treatments, and digital advancements.

IRA, WHO, FDA, ADA, NIH, EMA. 
Any Questions